Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.30 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.30 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22446918 | 0.81 | NPSR1 (0.38) | MEN1ALDH1A1HTTKMT2A | |
| SCHEMBL21885988 | 0.81 | ALDH1A1 (0.36) | MEN1ALDH1A1KMT2A | |
| SCHEMBL21163177 | 0.78 | ALDH1A1 (0.37) | MEN1ALDH1A1HTTKMT2APIK3CD | |
| SCHEMBL21886024 | 0.74 | ALDH1A1 (0.37) | MEN1ALDH1A1HTTKMT2A | |
| SCHEMBL18571259 | 0.73 | ALDH1A1 (0.43) | ALDH1A1KMT2A | |
| SCHEMBL21163174 | 0.73 | ALDH1A1 (0.34) | MEN1ALDH1A1HTTKMT2A | |
| SCHEMBL21162921 | 0.73 | ALDH1A1 (0.37) | MEN1ALDH1A1HTTKMT2A | |
| SCHEMBL18571397 | 0.71 | KDM4E (0.44) | MEN1ALDH1A1HTTKMT2A | |
| SCHEMBL21886084 | 0.71 | APLNR (0.39) | MEN1ALDH1A1KMT2A | |
| SCHEMBL21162922 | 0.70 | ALDH1A1 (0.33) | MEN1ALDH1A1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190192497-A1 | ANTIBODY-RECRUITING MOLECULES FOR THE TREATMENT OF CANCER | KLEO PHARMACEUTICALS, INC. | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190192497-A1 | ANTIBODY-RECRUITING MOLECULES FOR THE TREATMENT OF CANCER | PLAUR, C3AR1, C5AR1 | MEN1 1142/4885ALDH1A1 3673/4885HTT 4302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.